TNFRSF18 and neoplasm: In this study, we also demonstrated that HF10 virotherapy combined with a GITR-targeting mAb in local tumor sites at more clinical appropriate lower and safer doses, elicits tumor lysis by augmented systemic tumor-specific CD8+ T cell activity with negligible toxicity.